{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:06:56Z","timestamp":1765753616925,"version":"3.48.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastrointestinal neuroendocrine tumors (GI-NETs) lack effective targeted options beyond somatostatin analogs and mTOR inhibitors. Spleen tyrosine kinase (SYK) is a non-receptor kinase with emerging roles in solid tumors and available small-molecule inhibitors. We explored whether SYK is a plausible therapeutic target in GI-NET using two human cell lines. SYK expression in GI-NET cells was confirmed by immunofluorescence. Cells were exposed to a selective SYK inhibitor (BI-1002494), and proliferation was quantified using both 2D and 3D models. Both GI-NET models expressed SYK and exhibited reduced growth upon SYK blockade, with dose-dependent suppression of viability and increased cytotoxicity relative to vehicle. In spheroid assays, morphologic changes and reduced size were observed. These pilot data suggest SYK as a targetable vulnerability in GI-NET and support formal dose\u2013response studies, genetic validation, and combination strategies with standard-of-care agents. Given the clinical availability of SYK inhibitors, these findings provide a rationale for translational studies in GI-NET.<\/jats:p>","DOI":"10.1038\/s41417-025-00979-5","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:53:36Z","timestamp":1760615616000},"page":"1303-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spleen tyrosine kinase (SYK) inhibition suppresses growth of gastrointestinal neuroendocrine tumor cells: a pilot study in two cell lines"],"prefix":"10.1038","volume":"32","author":[{"given":"Angeliki","family":"Ditsiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-3443","authenticated-orcid":false,"given":"Viviana","family":"Vella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-6135","authenticated-orcid":false,"given":"Francesca","family":"D\u2019Este","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-6292","authenticated-orcid":false,"given":"Teresa","family":"Gagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"979_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/receptors3020008","volume":"3","author":"L Toffoli","year":"2024","unstructured":"Toffoli L, Ditsiou A, Gagliano T. Exploring emerging therapeutic targets and opportunities in neuroendocrine tumors: updates on receptor tyrosine kinases. Receptors. 2024;3:145\u201354.","journal-title":"Receptors"},{"key":"979_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/endrev\/bnad006","volume":"44","author":"R Garcia-Carbonero","year":"2023","unstructured":"Garcia-Carbonero R, Anton-Pascual B, Modrego A, Del Carmen Riesco-Martinez M, Lens-Pardo A, Carretero-Puche C, et al. Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?. Endocr Rev. 2023;44:724\u201336.","journal-title":"Endocr Rev"},{"key":"979_CR3","doi-asserted-by":"publisher","first-page":"R315","DOI":"10.1530\/ERC-17-0012","volume":"24","author":"A Di Domenico","year":"2017","unstructured":"Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24:R315\u201334.","journal-title":"Endocr Relat Cancer"},{"key":"979_CR4","doi-asserted-by":"publisher","first-page":"17162","DOI":"10.18632\/oncotarget.7751","volume":"7","author":"G Fu","year":"2016","unstructured":"Fu G, Somasundaram RT, Jessa F, Srivastava G, MacMillan C, Witterick I, et al. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Oncotarget. 2016;7:17162\u201381.","journal-title":"Oncotarget"},{"key":"979_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0002-9440(10)64017-5","volume":"158","author":"L K\u00f6lby","year":"2001","unstructured":"K\u00f6lby L, Bernhardt P, Ahlman H, W\u00e4ngberg B, Johanson V, Wigander A, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol. 2001;158:745\u201355.","journal-title":"Am J Pathol"},{"key":"979_CR6","first-page":"e250052","volume":"5","author":"L Toffoli","year":"2025","unstructured":"Toffoli L, Ditsiou A, Triboli L, Hamm V, Moschioni E, D\u2019Este F, et al. FAK inhibition disrupts tumor growth, apoptosis, and transcriptional regulation in GI-NETs. Endocr Oncol. 2025;5:e250052.","journal-title":"Endocr Oncol"},{"key":"979_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1530\/EC-19-0192","volume":"8","author":"G Bresciani","year":"2019","unstructured":"Bresciani G, Ditsiou A, Cilibrasi C, Vella V, Rea F, Schiavon M, et al. EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?. Endocr Connect. 2019;8:680\u201390.","journal-title":"Endocr Connect"},{"key":"979_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306027","volume":"11","author":"V Vella","year":"2024","unstructured":"Vella V, Ditsiou A, Chalari A, Eravci M, Wooller SK, Gagliano T, et al. Kinome-wide synthetic lethal screen identifies PANK4 as a modulator of temozolomide resistance in glioblastoma. Adv Sci. 2024;11:2306027.","journal-title":"Adv Sci"},{"key":"979_CR9","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1172\/JCI128313","volume":"130","author":"T Gagliano","year":"2020","unstructured":"Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, et al. PIK3C\u03b4 expression by fibroblasts promotes triple-negative breast cancer progression. J Clin Invest. 2020;130:3188\u2013204.","journal-title":"J Clin Invest"},{"key":"979_CR10","doi-asserted-by":"publisher","first-page":"eabc3099","DOI":"10.1126\/sciadv.abc3099","volume":"6","author":"A Ditsiou","year":"2020","unstructured":"Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al. The structure-function relationship of oncogenic LMTK3. Sci Adv. 2020;6:eabc3099.","journal-title":"Sci Adv"},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.tips.2024.08.006","volume":"45","author":"S Joshi","year":"2024","unstructured":"Joshi S. New insights into SYK targeting in solid tumors. Trends Pharm Sci. 2024;45:904\u201318.","journal-title":"Trends Pharm Sci"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00979-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:19Z","timestamp":1765753339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00979-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00979-5","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"type":"print","value":"0929-1903"},{"type":"electronic","value":"1476-5500"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TG is Senior Associated Editor of CGT, while AD and VV are Editorial Board member of the journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}